– Improvement in Serum Neurofilament Light Chain Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo –
– NfL Effect Consistent With Recently Released Data from Separate,.
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting 11.10.2023 / 12:30 CET/CEST The issuer is solely responsible for.
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific Conferences in October 04.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific Conferences in October NEW YORK, October 4, 2023 – I.